In this regard, we chose candidate compound 9 based on its potent MCT1 and MCT4 inhibition and previously demonstrated ability to reduce tumor growth in a WiDr mouse xenograft model [32, 33]. The gene discussed is SLC16A1; the disease is neoplasm.